enGene Therapeutics ENGN
NASDAQ ENGN
$2.41 +0.13 (+5.70%)
At close: Nov 13, 2026 · 4:00 PM EST

enGene Therapeutics (ENGN) Net Debt Issuances and Repayments (2023 - 2026)

Updated

Analysis

enGene Therapeutics (ENGN) Net Debt Issuances and Repayments (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Debt Issuance (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -5.28 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 2.28 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 9.48 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -682.00 Mn
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 4.91 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -3.05 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -19.00 Mn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -87.00 Mn
10 enGene Therapeutics 161.50 Mn -832.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2026 25.00 Mn
Jan 31, 2024 22.50 Mn
Jul 31, 2023 30.00 Mn
API Access

enGene Therapeutics Net Debt Issuances and Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-debt-issuances-and-repayments&ticker=ENGN&period=max&api_key=YOUR_API_KEY